RxDoctor Payments DataLook up a doctor →

David Salek, MD

Interventional Pain Medicine · Jacksonville, FLNPI 1285078832

Payments from drug & device makers

$24,881in general payments, 2019–2025

Across 490 payments — averaging $50.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Nevro Corp.$6K
  • Medtronic$4K
  • Abbott$3K
  • Relievant Medsystems, Inc.$2K
  • AbbVie$1K
  • plus $3K from 40 others

What the payments were for

  • Consulting fees$5552%
  • Travel & lodging$6,77927%
  • Food & beverage$17,34770%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,881 in reported general payments places this provider in the 80th percentile of 278 interventional pain medicine providers in Florida.

See all interventional pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$388,676
Medicare patients
418
Services billed
9,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen714$13,904
BotoxOnabotulinumtoxina12$13,676
Xtampza ErOxycodone Myristate12$10,930
OxycontinOxycodone Hcl12$9,339
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen253$6,232
Pregabalin205$3,464
Celecoxib150$2,351
Oxycodone Hcl127$2,021
Tramadol Hcl332$1,949
Gabapentin191$1,923
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$1,387
Lidocaine12$901
Morphine Sulfate25$529
Baclofen77$515
Hydromorphone Hcl21$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$1,094$13,67612 claims
Collegium Pharmaceutical, Inc.Xtampza Er$200$10,93012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 278 interventional pain medicine providers in Florida.

Other interventional pain medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →